Compare HTFL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTFL | VCEL |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2025 | 1996 |
| Metric | HTFL | VCEL |
|---|---|---|
| Price | $48.49 | $40.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $38.20 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.1M | 439.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.37 | 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | $176,034,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $27.66 | $19.40 |
| Revenue Next Year | $23.55 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.92 | 16.45 |
| 52 Week Low | $20.13 | $28.95 |
| 52 Week High | $51.78 | $49.32 |
| Indicator | HTFL | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 40.84 |
| Support Level | $47.13 | $35.45 |
| Resistance Level | $51.48 | $41.25 |
| Average True Range (ATR) | 2.40 | 1.17 |
| MACD | -0.71 | -0.17 |
| Stochastic Oscillator | 64.86 | 40.51 |
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.